SMT201600351B - Composti antivirali - Google Patents

Composti antivirali

Info

Publication number: SMT201600351B
Authority: SM; San Marino
Prior art keywords: antiviral compounds; antiviral; compounds
Prior art date: 2009-05-13

Application number

SM201600351T

Other languages

English (en)

Inventor

Hongyan Guo

Darryl Kato

Thorsten A Kirschberg

Hongtao Liu

John O Link

Michael L Mitchell

Jay P Parrish

Neil Squires

Jianyu Sun

James Taylor

Elizabeth M Bacon

Eda Canales

Aesop Cho

Choung U Kim

Jeromy J Cottell

Manoj C Desai

Randall L Halcomb

Evan S Krygowski

Scott E Lazerwith

Qi Liu

Richard Mackman

Hyung-Jung Pyun

Joseph H Saugier

James D Trenkle

Winston C Tse

Randall W Vivian

Scott D Schroeder

William J Watkins

Lianhong Xu

Zheng-Yu Yang

Terry Kellar

Xiaoning Sheng

Michael O'neil Hanrahan Clarke

Chien-Hung Chou

Michael Graupe

Haolun Jin

Ryan Mcfadden

Michael R Mish

Samuel E Metobo

Barton W Phillips

Chandarsekar Venkataramani

Original Assignee

Gilead Pharmasset Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-13

Filing date

2016-10-05

Publication date

2016-11-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42645241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600351(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-10-05 Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc

2016-11-10 Publication of SMT201600351B publication Critical patent/SMT201600351B/it

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

SM201600351T 2009-05-13 2016-10-05 Composti antivirali SMT201600351B (it)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US17797209P	2009-05-13	2009-05-13
US22474509P	2009-07-10	2009-07-10
US23876009P	2009-09-01	2009-09-01
EP10720970.2A EP2430014B1 (en)	2009-05-13	2010-05-12	Antiviral compounds

Publications (1)

Publication Number	Publication Date
SMT201600351B true SMT201600351B (it)	2016-11-10

Family

ID=42645241

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SM20170570T SMT201700570T1 (it)	2009-05-13	2010-05-12	Composti antivirali
SM201500284T SMT201500284B (it)	2009-05-13	2015-11-19	Composti antivirali
SM201600351T SMT201600351B (it)	2009-05-13	2016-10-05	Composti antivirali

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SM20170570T SMT201700570T1 (it)	2009-05-13	2010-05-12	Composti antivirali
SM201500284T SMT201500284B (it)	2009-05-13	2015-11-19	Composti antivirali

Country Status (40)

Country	Link
US (8)	US8088368B2 (it)
EP (6)	EP2857394A1 (it)
JP (7)	JP5582662B2 (it)
KR (8)	KR20140122705A (it)
CN (8)	CN104211713B (it)
AP (2)	AP2016008993A0 (it)
AR (1)	AR076765A1 (it)
AU (1)	AU2010249043B2 (it)
BR (3)	BRPI1010795B1 (it)
CA (2)	CA2761258C (it)
CL (1)	CL2011002825A1 (it)
CO (1)	CO6470842A2 (it)
CY (4)	CY1116942T1 (it)
DK (3)	DK3002281T3 (it)
EA (5)	EA037281B1 (it)
EC (1)	ECSP11011517A (it)
ES (4)	ES2646131T3 (it)
FR (1)	FR16C0005I2 (it)
HK (1)	HK1253517B (it)
HR (3)	HRP20151000T8 (it)
HU (4)	HUE036906T2 (it)
IL (5)	IL216254A (it)
LT (3)	LT3002281T (it)
ME (3)	ME02536B (it)
MX (6)	MX360800B (it)
NL (1)	NL300796I2 (it)
NO (3)	NO3002281T3 (it)
NZ (3)	NZ596444A (it)
PE (2)	PE20150202A1 (it)
PL (4)	PL2873665T3 (it)
PT (4)	PT3309157T (it)
RS (3)	RS54386B8 (it)
SG (2)	SG10201402280QA (it)
SI (4)	SI3002281T1 (it)
SM (3)	SMT201700570T1 (it)
TW (7)	TW202042807A (it)
UA (1)	UA121454C2 (it)
UY (1)	UY32629A (it)
WO (1)	WO2010132601A1 (it)
ZA (1)	ZA201108436B (it)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2906207T3 (es)	2003-05-30	2022-04-13	Gilead Pharmasset Llc	Análogos de nucleósidos fluorados modificados
NZ582692A (en) *	2007-07-05	2012-05-25	Array Biopharma Inc	Pyrimidyl cyclopentanes as akt protein kinase inhibitors
EA201190007A1 (ru)	2008-12-03	2012-06-29	Пресидио Фармасьютикалс, Инк.	Ингибиторы ns5a вгс
BRPI0922366B8 (pt)	2008-12-03	2021-05-25	Presidio Pharmaceuticals Inc	composto, composição farmacêutica e uso de um composto
EP2367824B1 (en)	2008-12-23	2016-03-23	AbbVie Inc.	Anti-viral derivatives of pyrimidine
CN102245604A (zh)	2008-12-23	2011-11-16	雅培制药有限公司	抗病毒化合物
US8314135B2 (en)	2009-02-09	2012-11-20	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole antivirals
TWI438200B (zh) *	2009-02-17	2014-05-21	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
US8188132B2 (en)	2009-02-17	2012-05-29	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
US8394968B2 (en)	2009-02-17	2013-03-12	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8637561B2 (en) *	2009-02-17	2014-01-28	Enanta Pharmaceuticals, Inc.	Linked diimidazole derivatives
US8242156B2 (en)	2009-02-17	2012-08-14	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
WO2010096777A1 (en) *	2009-02-23	2010-08-26	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
US9765087B2 (en)	2009-02-27	2017-09-19	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US8101643B2 (en) *	2009-02-27	2012-01-24	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US8673954B2 (en)	2009-02-27	2014-03-18	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US8709999B2 (en)	2009-03-27	2014-04-29	Presidio Pharmaceuticals, Inc.	Substituted bicyclic HCV inhibitors
US8796466B2 (en)	2009-03-30	2014-08-05	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TW201038559A (en) *	2009-04-09	2010-11-01	Bristol Myers Squibb Co	Hepatitis C virus inhibitors
US8143414B2 (en)	2009-04-13	2012-03-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2010120935A1 (en)	2009-04-15	2010-10-21	Abbott Laboratories	Anti-viral compounds
MX2011011136A (es) *	2009-04-24	2011-11-18	Tibotec Pharm Ltd	Eteres diarilicos.
EP2430015B1 (en) *	2009-05-12	2015-06-17	Merck Sharp & Dohme Corp.	Fused tricyclic compounds useful for the treatment of viral diseases
HUE036906T2 (hu)	2009-05-13	2018-08-28		Antivirális vegyületek
AU2010253791A1 (en) *	2009-05-29	2011-11-24	Merck Sharp & Dohme Corp.	Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
US8138215B2 (en) *	2009-05-29	2012-03-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
AU2010253790A1 (en) *	2009-05-29	2011-12-15	Merck Sharp & Dohme Corp.	Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C
US8211928B2 (en)	2009-05-29	2012-07-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8937150B2 (en)	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
US9394279B2 (en)	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
RS53856B1 (sr) *	2009-06-11	2015-08-31	Abbvie Bahamas Ltd.	Heterociklična jedinjenja kao inhibitori hepatitis c virusa
US8716454B2 (en)	2009-06-11	2014-05-06	Abbvie Inc.	Solid compositions
US8609648B2 (en) *	2009-07-02	2013-12-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
JP2012533569A (ja)	2009-07-16	2012-12-27	ヴァーテックスファーマシューティカルズ、インコーポレイテッド	フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体
US8623899B2 (en) *	2009-08-07	2014-01-07	Janssen Research & Development Ireland	Bis-benzimidazole derivatives as hepatitis C virus inhibitors
US9045463B2 (en) *	2009-08-07	2015-06-02	Janssen R&D Ireland	Phenyl ethynyl derivatives as hepatitis C virus inhibitors
CN102480971B (zh)	2009-09-04	2014-11-26	杨森制药公司	化合物
WO2011031904A1 (en) *	2009-09-11	2011-03-17	Enanta Pharmaceuticals, Inc	Hepatitis c virus inhibitors
US8759332B2 (en) *	2009-09-11	2014-06-24	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
EP2475254A4 (en) *	2009-09-11	2013-05-22	Enanta Pharm Inc	HEPATITIS C-VIRUS HEMMER
US8703938B2 (en) *	2009-09-11	2014-04-22	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8927709B2 (en) *	2009-09-11	2015-01-06	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8822700B2 (en) *	2009-09-11	2014-09-02	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8815928B2 (en) *	2009-09-11	2014-08-26	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
UA108211C2 (uk)	2009-11-04	2015-04-10	Янссен Рід Айрленд	Бензімідазолімідазольні похідні
US20110274648A1 (en) *	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110269956A1 (en)	2009-11-11	2011-11-03	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110281910A1 (en) *	2009-11-12	2011-11-17	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
KR101768946B1 (ko) *	2009-12-04	2017-08-17	내셔날 헬스 리서치 인스티튜트	프롤린 유도체
US8653070B2 (en)	2009-12-14	2014-02-18	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CN104341401B (zh) *	2009-12-18	2017-02-15	北京凯因科技股份有限公司	C型肝炎病毒复制的新型抑制剂
JP2013514982A (ja)	2009-12-18	2013-05-02	イデニクプハルマセウティカルス，インコーポレイテッド	５，５−縮合アリーレン又はヘテロアリーレンｃ型肝炎ウイルス阻害剤
AU2010336355A1 (en) *	2009-12-24	2012-07-05	Vertex Pharmaceuticals Incorporated	Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en)	2009-12-30	2013-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8933110B2 (en)	2010-01-25	2015-01-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
WO2011091417A1 (en)	2010-01-25	2011-07-28	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
EP2528926A4 (en) *	2010-01-28	2013-06-19	Boehringer Ingelheim Int	HEPATITIS C INHIBITOR COMPOUNDS
US8623814B2 (en) *	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
US8178531B2 (en) *	2010-02-23	2012-05-15	Enanta Pharmaceuticals, Inc.	Antiviral agents
US9060971B2 (en)	2010-03-04	2015-06-23	Enanta Pharmaceuticals, Inc.	Combination pharmaceutical agents as inhibitors of HCV replication
WO2011119860A1 (en) *	2010-03-24	2011-09-29	Vertex Pharmaceuticals Incorporated	Analogues for the treatment or prevention of flavivirus infections
MX2012010918A (es) *	2010-03-24	2013-01-18	Vertex Pharma	Analogos para el tratamiento o prevencion de infecciones por flavivirus.
US9127021B2 (en)	2010-04-09	2015-09-08	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US9125904B1 (en)	2010-05-11	2015-09-08	Achillion Pharmaceuticals, Inc.	Biphenyl imidazoles and related compounds useful for treating HCV infections
US20130296311A1 (en) *	2010-05-28	2013-11-07	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
EP2575819A4 (en)	2010-06-04	2013-11-27	Enanta Pharm Inc	INHIBITORS OF HEPATITIS C VIRUS
US20130310427A1 (en) *	2010-06-09	2013-11-21	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a protein
NZ605440A (en)	2010-06-10	2014-05-30	Abbvie Bahamas Ltd	Solid compositions comprising an hcv inhibitor
EP2603080A4 (en)	2010-08-12	2014-01-22	Enanta Pharm Inc	HEPATITIS C-VIRUS HEMMER
US20120195857A1 (en) *	2010-08-12	2012-08-02	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
AR082619A1 (es) *	2010-08-13	2012-12-19	Hoffmann La Roche	Inhibidores del virus de la hepatitis c
CA2809261A1 (en)	2010-08-26	2012-03-01	Rfs Pharma, Llc	Potent and selective inhibitors of hepatitis c virus
US8999967B2 (en)	2010-09-29	2015-04-07	Presidio Pharmaceuticals, Inc.	Tricyclic fused ring inhibitors of hepatitis C
US9156823B2 (en) *	2010-11-17	2015-10-13	Gilead Pharmasset Llc	Antiviral compounds
RU2452735C1 (ru) *	2010-11-30	2012-06-10	Александр Васильевич Иващенко	Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
US20150232455A1 (en) *	2010-12-15	2015-08-20	Allan C. Krueger	Anti-viral compounds
US20140364616A1 (en) *	2010-12-15	2014-12-11	Abbvie Inc.	Anti-viral compounds
WO2012083058A2 (en) *	2010-12-15	2012-06-21	Abbott Laboratories	Anti-viral compounds
AU2011349844B2 (en)	2010-12-20	2017-06-01	Gilead Sciences, Inc.	Combinations for treating HCV
WO2012087976A2 (en) *	2010-12-21	2012-06-28	Intermune, Inc.	Novel inhibitors of hepatitis c virus replication
US8552047B2 (en)	2011-02-07	2013-10-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP2012188400A (ja) *	2011-03-11	2012-10-04	Tosoh Corp	ジチエノベンゾジチオフェンの製造方法
WO2012122716A1 (en) *	2011-03-17	2012-09-20	Merck Sharp & Dohme Corp.	Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US8835456B1 (en)	2011-03-18	2014-09-16	Achillion Pharmaceuticals, Inc.	NS5A inhibitors useful for treating HCV
US20120252721A1 (en) *	2011-03-31	2012-10-04	Idenix Pharmaceuticals, Inc.	Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9546160B2 (en) *	2011-05-12	2017-01-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
JP5669984B2 (ja)	2011-05-18	2015-02-18	エナンタファーマシューティカルズインコーポレイテッド	５−アザスピロ［２．４］ヘプタン−６−カルボン酸およびその誘導体の製造方法
MX357867B (es)	2011-05-27	2018-07-19	Achillion Pharmaceuticals Inc	Alifanos, ciclofanos, heterafanos, heterofanos, hetero-heterafanos y metalocenos sustituidos utiles para tratar infecciones por el vhc.
JP2014520822A (ja)	2011-07-09	2014-08-25	スンシネルアケプハルマカンパニーリミテッド	Ｃ型肝炎ウイルス阻害剤としてのスピロ化合物
PH12014500312A1 (en)	2011-08-08	2014-03-31	Lupin Ltd	Imidazole derivatives as antiviral agents
WO2013025975A1 (en) *	2011-08-17	2013-02-21	Glaxosmithkline Llc	Combination treatments for hepatitis c
KR20140065427A (ko) *	2011-08-24	2014-05-29	글락소스미스클라인 엘엘씨	Ｃ형 간염에 대한 조합 치료
WO2013030750A1 (en)	2011-09-01	2013-03-07	Lupin Limited	Antiviral compounds
UA116087C2 (uk) *	2011-09-16	2018-02-12	Гіліад Фармассет Елелсі	Композиція для лікування вірусу гепатиту c
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
DE112012003510T5 (de)	2011-10-21	2015-03-19	Abbvie Inc.	Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
CN104023726A (zh)	2011-10-21	2014-09-03	艾伯维公司	用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
AR088630A1 (es)	2011-11-03	2014-06-25	Theravance Inc	Inhibidores del virus de la hepatitis c
UA110354C2 (uk)	2011-11-16	2015-12-25	Гайлід Фармассет Елелсі	Противірусні сполуки
CA2858659A1 (en)	2011-12-28	2013-07-04	Janssen R&D Ireland	Hetero-bicyclic derivatives as hcv inhibitors
US9034832B2 (en)	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
EP2797586A1 (en) *	2011-12-29	2014-11-05	AbbVie Inc.	Solid compositions comprising an hcv inhibitor
US9326973B2 (en) *	2012-01-13	2016-05-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CA2862755A1 (en) *	2012-02-10	2013-08-15	Lupin Limited	Antiviral compounds with a dibenzooxaheterocycle moiety
KR20140129019A (ko) *	2012-02-14	2014-11-06	유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드	플라비비리다에 감염의 치료를 위한 스피로[2.4]헵탄
ITMI20120424A1 (it)	2012-03-19	2013-09-20	Rottapharm Spa	Composti chimici
US9206159B2 (en)	2012-04-25	2015-12-08	Theravance Biopharma R&D Ip, Llc	Piperazine-piperidine compounds as hepatitis C virus inhibitors
CN104302636B (zh)	2012-04-25	2017-03-29	施万生物制药研发Ip有限责任公司	C型肝炎病毒抑制剂
US9079887B2 (en) *	2012-05-16	2015-07-14	Gilead Sciences, Inc.	Antiviral compounds
US20130309196A1 (en) *	2012-05-16	2013-11-21	Gilead Sciences, Inc.	Antiviral compounds
US8969588B2 (en) *	2012-06-05	2015-03-03	Gilead Pharmasset Llc	Solid forms of an antiviral compound
US9056860B2 (en) *	2012-06-05	2015-06-16	Gilead Pharmasset Llc	Synthesis of antiviral compound
TWI610916B (zh)	2012-08-03	2018-01-11	廣東東陽光藥業有限公司	作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
TW201412709A (zh) *	2012-09-28	2014-04-01	Sunshine Lake Pharma Co Ltd	作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用
CN103848821B (zh) *	2012-11-29	2016-10-12	广东东阳光药业有限公司	作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途
WO2014082380A1 (en)	2012-11-29	2014-06-05	Sunshine Lake Pharma Co., Ltd.	Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
CN103848819B (zh) *	2012-11-29	2017-04-12	广东东阳光药业有限公司	作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们在药物中的应用
CN103880823B (zh) *	2012-12-21	2017-12-05	广东东阳光药业有限公司	作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用
CN104144682A (zh)	2013-01-31	2014-11-12	吉利德法莫赛特有限责任公司	两个抗病毒化合物的联用制剂
RU2518369C1 (ru) *	2013-02-07	2014-06-10	Общество с ограниченной ответственностью "Интеллектуальный Диалог"	Алкил [2-(2-{5-[4-(4-{2-[1-(2-метоксикарбониламино-ацетил)-пирролидин-2-ил]-3н-имидазол-4-ил}-фенил)-бута-1,3-диинил]-1н-имидазол-2-ил}-пирролидин-1-ил)-2-оксо-этил]-карбамат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
RU2507201C1 (ru) *	2013-02-07	2014-02-20	Александр Васильевич Иващенко	Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
TW201439060A (zh) *	2013-02-27	2014-10-16	Sunshine Lake Pharma Co Ltd	作爲丙型肝炎抑制劑的橋環化合物及其藥物組合物和用途
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
US20140357595A1 (en) *	2013-06-04	2014-12-04	Gilead Pharmasset Llc	Methods of preventing and treating recurrence of a hepatitis c virus infection in a subject after the subject has received a liver transplant
CN105837561B (zh) *	2013-06-06	2019-06-28	上海爱博医药科技有限公司	抑制丙肝病毒的化合物、药物组合物及其应用
US9717712B2 (en)	2013-07-02	2017-08-01	Bristol-Myers Squibb Company	Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en)	2013-07-02	2015-01-22	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
WO2015009744A1 (en)	2013-07-17	2015-01-22	Bristol-Myers Squibb Company	Combinations comprising biphenyl derivatives for use in the treatment of hcv
KR102239196B1 (ko)	2013-08-27	2021-04-12	길리애드 파마셋 엘엘씨	2종의 항바이러스 화합물의 조합 제제
CN104418785A (zh) *	2013-09-05	2015-03-18	浙江九洲药业股份有限公司	一种药物中间体的制备方法
US20160229866A1 (en)	2013-09-20	2016-08-11	Idenix Pharmaceuticals Inc.	Hepatitis c virus inhibitors
CN104610272B (zh) *	2013-11-05	2017-03-29	上海唐润医药科技有限公司	环状黄酮或异黄酮类化合物及其用途
KR101561964B1 (ko)	2013-11-15	2015-10-20	한국과학기술연구원	옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
US20150150897A1 (en)	2013-12-02	2015-06-04	Gilead Pharmasset Llc	Methods of treating hepatitis c virus infection in subjects with cirrhosis
CN104725365B (zh) *	2013-12-23	2019-02-26	南京圣和药业股份有限公司	丙型肝炎病毒抑制剂及其应用
TW201609785A (zh)	2013-12-23	2016-03-16	吉李德製藥公司	固體型之抗病毒化合物
EP3091010A4 (en) *	2013-12-31	2017-10-04	Nanjing Sanhome Pharmaceutical Co., Ltd.	9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene hepatitis c virus inhibitor and application thereof
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
WO2015110048A1 (en) *	2014-01-23	2015-07-30	Sunshine Lake Pharma Co., Ltd.	Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
CN104860931A (zh) *	2014-02-21	2015-08-26	常州寅盛药业有限公司	丙肝病毒抑制剂及其制药用途
CN108084172A (zh) *	2014-02-21	2018-05-29	常州寅盛药业有限公司	抗丙肝病毒化合物
WO2015184644A1 (zh) *	2014-06-06	2015-12-10	爱博新药研发(上海)有限公司	抑制丙肝病毒的化合物、药物组合物及其应用
CN104140417B (zh) *	2014-06-11	2016-04-06	苏州景泓生物技术有限公司	合成gs5885用的中间体的先期化合物的合成方法
TWI721947B (zh)	2014-06-11	2021-03-21	美商基利法瑪席特有限責任公司	抗病毒化合物的固態形式
CN105524049B (zh) *	2014-09-28	2018-11-06	正大天晴药业集团股份有限公司	氘代的丙型肝炎病毒ns5a蛋白抑制剂
CN104513147B (zh) *	2014-11-20	2016-05-11	上海众强药业有限公司	芴乙酮衍生物的制备方法
WO2016095814A1 (en) *	2014-12-16	2016-06-23	Sunshine Lake Pharma Co., Ltd.	Bridged ring compounds as hepatitis c virus inhibitors and preparation thereof
WO2016103232A1 (en) *	2014-12-24	2016-06-30	Granules India Limited	An improved process for the preparation of hcv inhibitor
CN104530016A (zh) *	2014-12-25	2015-04-22	上海泓博智源医药技术有限公司	一种雷迪帕韦的制备方法及其中间体
ES2892123T3 (es)	2014-12-26	2022-02-02	Univ Emory	Derivados antivíricos de N4-hidroxicitidina
US20180008624A1 (en)	2015-02-13	2018-01-11	Sandoz Ag	Pharmaceutical Compositions Comprising Ledipasvir And Sofosbuvir
CN105985355B (zh) *	2015-03-01	2020-05-05	南京圣和药业股份有限公司	稠合三环类肝炎病毒抑制剂及其应用
HUE038059T2 (hu)	2015-03-04	2018-10-29	Gilead Sciences Inc	Toll-like receptor moduláló 4,6-diamino-pirido[3,2-D]pirimidin vegyületek
WO2016145269A1 (en)	2015-03-12	2016-09-15	Teva Pharmaceuticals International Gmbh	Solid state forms ledipasvir and processes for preparation of ledipasvir
CN104829599B (zh) *	2015-03-17	2017-06-09	上海众强药业有限公司	雷迪帕韦及其衍生物的制备方法及用于制备雷迪帕韦的中间体化合物
US20160375017A1 (en)	2015-06-26	2016-12-29	Abbvie Inc.	Solid Pharmaceutical Compositions for Treating HCV
CN105017228A (zh) *	2015-07-03	2015-11-04	上海众强药业有限公司	一种雷迪帕韦中间体单硫酸盐、其晶型及其制备方法
CR20180023A (es)	2015-07-24	2018-03-20	Newlink Genetics Corp	Sales y profármacos de 1-metil-d-triptofano
WO2017023631A1 (en)	2015-08-06	2017-02-09	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
KR101919194B1 (ko) *	2015-09-15	2018-11-15	주식회사 엘지화학	헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
CN105294713A (zh) *	2015-10-09	2016-02-03	重庆康施恩化工有限公司	Velpatasvir中间体及其制备方法
WO2017072596A1 (en)	2015-10-26	2017-05-04	Optimus Drugs (P) Ltd	An improved process for the preparation of ledipasvir
WO2017072714A1 (en)	2015-10-30	2017-05-04	Lupin Limited	Stable ledipasvir premix and process of preparation thereof
CN108349945B (zh) *	2015-11-06	2021-10-29	江苏豪森药业集团有限公司	Hcv抑制剂、其制备方法与应用
CN106117187B (zh) *	2016-01-12	2019-01-01	深圳市塔吉瑞生物医药有限公司	一种丙型肝炎病毒抑制剂、药物组合物及其应用
WO2017134548A1 (en)	2016-02-01	2017-08-10	Lupin Limited	Process for the preparation of ledipasvir and intermediates thereof
WO2017145028A1 (en) *	2016-02-26	2017-08-31	Glenmark Pharmaceuticals Limited	Process for preparation of ledipasvir
WO2017184670A2 (en)	2016-04-22	2017-10-26	Gilead Sciences, Inc.	Methods for treating zika virus infections
EA201892448A1 (ru)	2016-04-28	2019-06-28	Эмори Юниверсити	Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
EP3454862B1 (en)	2016-05-10	2024-09-11	C4 Therapeutics, Inc.	Spirocyclic degronimers for target protein degradation
WO2017197046A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197051A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Amine-linked c3-glutarimide degronimers for target protein degradation
EP4491236A3 (en)	2016-05-10	2025-04-02	C4 Therapeutics, Inc.	Heterocyclic degronimers for target protein degradation
WO2017195147A1 (en)	2016-05-12	2017-11-16	Lupin Limited	Process for the preparation of ledipasvir and intermediates thereof
KR102202984B1 (ko)	2016-05-27	2021-01-13	길리애드 사이언시즈, 인코포레이티드	Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법
BR102017011025A2 (pt)	2016-06-02	2017-12-19	Gilead Pharmasset Llc	Formulation of combination of three antiviral compounds
CN107663196A (zh) *	2016-07-27	2018-02-06	广东东阳光药业有限公司	制备化合物的方法
WO2018035410A1 (en) *	2016-08-19	2018-02-22	Temple University-Of The Commonwealth System Of Higher Education	Compositions and methods of treatment using expanded-size dna analogs
US10370342B2 (en)	2016-09-02	2019-08-06	Gilead Sciences, Inc.	Toll like receptor modulator compounds
ES2826748T3 (es)	2016-09-02	2021-05-19	Gilead Sciences Inc	Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
JP2018095561A (ja) *	2016-12-08	2018-06-21	金剛化学株式会社	ジフェニルアゼチジン誘導体の製造方法
CN106632275B (zh) *	2016-12-20	2018-03-06	上海同昌生物医药科技有限公司	一种雷迪帕韦的制备方法及制备雷迪帕韦的中间体
RU2650610C1 (ru)	2017-02-28	2018-04-16	Васильевич Иващенко Александр	Противовирусная композиция и способ ее применения
US10392370B2 (en)	2017-03-13	2019-08-27	Optimus Drugs Pvt Ltd	Process for the preparation of Daclatasvir dihydrochloride and its intermediates
JOP20180040A1 (ar)	2017-04-20	2019-01-30	Gilead Sciences Inc	مثبطات pd-1/pd-l1
CN110769830A (zh)	2017-05-12	2020-02-07	马瓦隆治疗有限公司	作为ii组代谢型谷氨酸受体的别构调节剂的取代的杂环化合物
EP3641762A4 (en)	2017-06-20	2021-03-10	C4 Therapeutics, Inc.	N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
ES2995458T3 (en)	2017-12-07	2025-02-10	Univ Emory	N4-hydroxycytidine derivative and anti-viral uses related thereto
WO2019160882A1 (en)	2018-02-13	2019-08-22	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
CN112041311B (zh)	2018-04-19	2023-10-03	吉利德科学公司	Pd-1/pd-l1抑制剂
JP2021523942A (ja)	2018-05-15	2021-09-09	ユニバーシティ・オブ・ルイスビル・リサーチ・ファウンデーション・インコーポレイテッドＵｎｉｖｅｒｓｉｔｙＯｆＬｏｕｉｓｖｉｌｌｅＲｅｓｅａｒｃｈＦｏｕｎｄａｔｉｏｎ，Ｉｎｃ．	療法における使用のためのウロリシンａおよびその誘導体
KR20230159715A (ko)	2018-07-13	2023-11-21	길리애드 사이언시즈, 인코포레이티드	Pd-1/pd-l1 억제제
EP3870566A1 (en)	2018-10-24	2021-09-01	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
TW202106677A (zh) *	2019-04-25	2021-02-16	美商貝達醫藥公司	用於治療c型肝炎病毒感染之ns5a的二胺甲酸酯抑制劑
US20220305115A1 (en)	2019-06-18	2022-09-29	Janssen Sciences Ireland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
MX2022010681A (es) *	2020-02-28	2023-03-21	Remix Therapeutics Inc	Compuestos y metodos para modular el empalme.
WO2021209563A1 (en)	2020-04-16	2021-10-21	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4079748A1 (en)	2021-04-23	2022-10-26	Insusense ApS	Modulators of sortilin activity
EP4089102A1 (en)	2021-05-14	2022-11-16	Insusense ApS	Modulators of sortilin activity
WO2022246072A1 (en) *	2021-05-21	2022-11-24	Gilead Sciences, Inc.	Tetracyclic compounds for the treatment of zika virus infection
EP4341266A1 (en)	2021-05-21	2024-03-27	Gilead Sciences, Inc.	Pentacyclic derivatives as zika virus inhibitors
MX2024000299A (es)	2021-07-09	2024-03-14	Aligos Therapeutics Inc	Compuestos antivirales.
US12065428B2 (en)	2021-09-17	2024-08-20	Aligos Therapeutics, Inc.	Anti-viral compounds
EP4476202A1 (en) *	2022-02-11	2024-12-18	Wave Life Sciences Ltd.	Stereoselective technologies for chiral compounds
CN117567414A (zh) *	2023-10-13	2024-02-20	濮阳惠成电子材料股份有限公司	一种光电材料中间体1-溴二苯并呋喃的合成方法

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816570A (en)	1982-11-30	1989-03-28	The Board Of Regents Of The University Of Texas System	Biologically reversible phosphate and phosphonate protective groups
US4968788A (en)	1986-04-04	1990-11-06	Board Of Regents, The University Of Texas System	Biologically reversible phosphate and phosphonate protective gruops
EP0533833B1 (en)	1990-06-13	1995-12-20	GLAZIER, Arnold	Phosphorous produgs
EP0481214B1 (en)	1990-09-14	1998-06-24	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Prodrugs of phosphonates
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
BRPI0513426A (pt)	2004-07-16	2007-11-27	Gilead Sciences Inc	processo de preparação de amino ácidos úteis na preparação de moduladores de receptores de peptìdeos
US7323447B2 (en) *	2005-02-08	2008-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8143288B2 (en) *	2005-06-06	2012-03-27	Bristol-Myers Squibb Company	Inhibitors of HCV replication
US8329159B2 (en) *	2006-08-11	2012-12-11	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7659270B2 (en) *	2006-08-11	2010-02-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7759495B2 (en)	2006-08-11	2010-07-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8303944B2 (en)	2006-08-11	2012-11-06	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
US7741347B2 (en) *	2007-05-17	2010-06-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JPWO2008156094A1 (ja)	2007-06-19	2010-08-26	杏林製薬株式会社	ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
US7728027B2 (en)	2007-08-08	2010-06-01	Bristol-Myers Squibb Company	Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en)	2007-08-08	2014-01-14	Bristol-Myers Squibb Company	Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
WO2009102318A1 (en)	2008-02-12	2009-08-20	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
KR101492672B1 (ko)	2008-02-13	2015-02-16	브리스톨-마이어스 스큅 컴퍼니	Ｃ형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸
US7704992B2 (en) *	2008-02-13	2010-04-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8147818B2 (en)	2008-02-13	2012-04-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
GB2457659A (en)	2008-02-19	2009-08-26	Malcolm Mulheron	Foldable meal tray
WO2010004843A1 (ja)	2008-07-08	2010-01-14	Ntn株式会社	減速装置
MX2011000060A (es)	2008-07-10	2011-02-22	Prosidion Ltd	Agonistas del receptor acoplado a la proteina g piperidinilo.
US7906655B2 (en) *	2008-08-07	2011-03-15	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8383094B2 (en)	2008-10-01	2013-02-26	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2010062821A1 (en)	2008-11-28	2010-06-03	Glaxosmithkline Llc	Anti-viral compounds, compositions, and methods of use
EA201190007A1 (ru) *	2008-12-03	2012-06-29	Пресидио Фармасьютикалс, Инк.	Ингибиторы ns5a вгс
BRPI0922366B8 (pt) *	2008-12-03	2021-05-25	Presidio Pharmaceuticals Inc	composto, composição farmacêutica e uso de um composto
WO2010091413A1 (en)	2009-02-09	2010-08-12	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
WO2010096462A1 (en)	2009-02-17	2010-08-26	Enanta Pharmaceuticals, Inc	Linked diimidazole derivatives
TWI438200B (zh)	2009-02-17	2014-05-21	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
WO2010096777A1 (en)	2009-02-23	2010-08-26	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
UY32462A (es)	2009-02-23	2010-09-30	Arrow Therapeutics Ltd	Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
MX2011008982A (es)	2009-02-27	2011-09-15	Enata Pharmaceuticals Inc	Inhibidores del virus de la hepatitis c.
CA2755642A1 (en)	2009-03-20	2010-09-23	Alios Biopharma, Inc.	Substituted nucleoside and nucleotide analogs
US9150554B2 (en)	2009-03-27	2015-10-06	Presidio Pharmaceuticals, Inc.	Fused ring inhibitors of hepatitis C
US8709999B2 (en)	2009-03-27	2014-04-29	Presidio Pharmaceuticals, Inc.	Substituted bicyclic HCV inhibitors
MA33209B1 (fr)	2009-03-27	2012-04-02	Merck Sharp & Dohme	Inhibiteurs de la replication du virus de l'hepatite c
US8796466B2 (en)	2009-03-30	2014-08-05	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TWI476190B (zh)	2009-03-30	2015-03-11	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
TW201038559A (en)	2009-04-09	2010-11-01	Bristol Myers Squibb Co	Hepatitis C virus inhibitors
US8143414B2 (en)	2009-04-13	2012-03-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2010120935A1 (en)	2009-04-15	2010-10-21	Abbott Laboratories	Anti-viral compounds
MX2011011136A (es)	2009-04-24	2011-11-18	Tibotec Pharm Ltd	Eteres diarilicos.
EP2430015B1 (en) *	2009-05-12	2015-06-17	Merck Sharp & Dohme Corp.	Fused tricyclic compounds useful for the treatment of viral diseases
HUE036906T2 (hu) *	2009-05-13	2018-08-28		Antivirális vegyületek
AU2010253791A1 (en)	2009-05-29	2011-11-24	Merck Sharp & Dohme Corp.	Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
US8138215B2 (en)	2009-05-29	2012-03-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
AU2010253790A1 (en)	2009-05-29	2011-12-15	Merck Sharp & Dohme Corp.	Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C
US8211928B2 (en)	2009-05-29	2012-07-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
RS53856B1 (sr)	2009-06-11	2015-08-31	Abbvie Bahamas Ltd.	Heterociklična jedinjenja kao inhibitori hepatitis c virusa
US8221737B2 (en)	2009-06-16	2012-07-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
WO2010148006A1 (en)	2009-06-16	2010-12-23	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
WO2011004276A1 (en)	2009-07-06	2011-01-13	Pfizer Limited	Hepatitis c virus inhibitors
JP2012533569A (ja)	2009-07-16	2012-12-27	ヴァーテックスファーマシューティカルズ、インコーポレイテッド	フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体
US8623899B2 (en)	2009-08-07	2014-01-07	Janssen Research & Development Ireland	Bis-benzimidazole derivatives as hepatitis C virus inhibitors
US9045463B2 (en)	2009-08-07	2015-06-02	Janssen R&D Ireland	Phenyl ethynyl derivatives as hepatitis C virus inhibitors
FR2949465B1 (fr)	2009-09-01	2011-08-12	Pf Medicament	Derives chromones, leur procede de preparation et leurs applications therapeutiques
US20120172368A1 (en)	2009-09-03	2012-07-05	Koen Vandyck	Bis-Benzimidazole Derivatives
CN102480971B (zh)	2009-09-04	2014-11-26	杨森制药公司	化合物
WO2011031904A1 (en)	2009-09-11	2011-03-17	Enanta Pharmaceuticals, Inc	Hepatitis c virus inhibitors
EP2475254A4 (en)	2009-09-11	2013-05-22	Enanta Pharm Inc	HEPATITIS C-VIRUS HEMMER
US8415374B2 (en)	2009-10-12	2013-04-09	Bristol-Myers Squibb Company	Combinations of hepatitis C virus inhibitors
WO2011050146A1 (en)	2009-10-23	2011-04-28	Glaxosmithkline Llc	Chemical compounds
UA108211C2 (uk)	2009-11-04	2015-04-10	Янссен Рід Айрленд	Бензімідазолімідазольні похідні
US20110274648A1 (en)	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110269956A1 (en)	2009-11-11	2011-11-03	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110281910A1 (en)	2009-11-12	2011-11-17	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
CA2782024A1 (en)	2009-11-25	2011-06-03	Schering Corporation	Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20110137633A1 (en)	2009-12-03	2011-06-09	Abbott Laboratories	Anti-viral compounds and methods of identifying the same
US8653070B2 (en)	2009-12-14	2014-02-18	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP2013514982A (ja)	2009-12-18	2013-05-02	イデニクプハルマセウティカルス，インコーポレイテッド	５，５−縮合アリーレン又はヘテロアリーレンｃ型肝炎ウイルス阻害剤
CN104341401B (zh)	2009-12-18	2017-02-15	北京凯因科技股份有限公司	C型肝炎病毒复制的新型抑制剂
US20130156731A1 (en)	2009-12-22	2013-06-20	Kevin X. Chen	Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
AU2010336355A1 (en)	2009-12-24	2012-07-05	Vertex Pharmaceuticals Incorporated	Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en)	2009-12-30	2013-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2011091446A1 (en)	2010-01-22	2011-07-28	Glaxosmithkline Llc	Chemical compounds
WO2011112429A1 (en)	2010-03-09	2011-09-15	Schering Corporation	Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
WO2011146401A1 (en)	2010-05-17	2011-11-24	Intermune, Inc.	Novel inhibitors of hepatitis c virus replication
NZ603310A (en) *	2010-05-21	2015-01-30	Gilead Sciences Inc	Heterocyclic flaviviridae virus inhibitors
TW201211047A (en) *	2010-06-10	2012-03-16	Gilead Sciences Inc	Methods for treating HCV
CA2809261A1 (en)	2010-08-26	2012-03-01	Rfs Pharma, Llc	Potent and selective inhibitors of hepatitis c virus
BR112013007696A2 (pt)	2010-09-29	2019-09-24	Merck Sharp & Dohme	composto, composição farmacêutica, usos do referido composto e da referida composição
WO2012048421A1 (en)	2010-10-14	2012-04-19	Boehringer Ingelheim International Gmbh	Hepatitis c inhibitor compounds
US9156823B2 (en)	2010-11-17	2015-10-13	Gilead Pharmasset Llc	Antiviral compounds
AU2011349844B2 (en) *	2010-12-20	2017-06-01	Gilead Sciences, Inc.	Combinations for treating HCV
WO2012087976A2 (en)	2010-12-21	2012-06-28	Intermune, Inc.	Novel inhibitors of hepatitis c virus replication
UA116087C2 (uk) *	2011-09-16	2018-02-12	Гіліад Фармассет Елелсі	Композиція для лікування вірусу гепатиту c
UA110354C2 (uk)	2011-11-16	2015-12-25	Гайлід Фармассет Елелсі	Противірусні сполуки
US8969588B2 (en) *	2012-06-05	2015-03-03	Gilead Pharmasset Llc	Solid forms of an antiviral compound
US8841340B2 (en) *	2012-08-17	2014-09-23	Gilead Sciences, Inc.	Solid forms of an antiviral compound

2010
- 2010-05-12 HU HUE15180635A patent/HUE036906T2/hu unknown
- 2010-05-12 SI SI201031554T patent/SI3002281T1/sl unknown
- 2010-05-12 PE PE2014001982A patent/PE20150202A1/es active IP Right Grant
- 2010-05-12 KR KR1020147016501A patent/KR20140122705A/ko not_active Ceased
- 2010-05-12 HR HRP20151000TT patent/HRP20151000T8/hr unknown
- 2010-05-12 LT LTEP15180635.3T patent/LT3002281T/lt unknown
- 2010-05-12 ES ES15180635.3T patent/ES2646131T3/es active Active
- 2010-05-12 SM SM20170570T patent/SMT201700570T1/it unknown
- 2010-05-12 HU HUE10720970A patent/HUE025983T2/en unknown
- 2010-05-12 TW TW109105841A patent/TW202042807A/zh unknown
- 2010-05-12 EA EA201790515A patent/EA037281B1/ru unknown
- 2010-05-12 MX MX2014005933A patent/MX360800B/es unknown
- 2010-05-12 CA CA2761258A patent/CA2761258C/en active Active
- 2010-05-12 BR BRPI1010795A patent/BRPI1010795B1/pt active IP Right Grant
- 2010-05-12 PL PL14175539T patent/PL2873665T3/pl unknown
- 2010-05-12 EP EP20140175570 patent/EP2857394A1/en not_active Withdrawn
- 2010-05-12 CN CN201410227574.2A patent/CN104211713B/zh active Active
- 2010-05-12 EA EA201490853A patent/EA201490853A1/ru unknown
- 2010-05-12 NO NO15180635A patent/NO3002281T3/no unknown
- 2010-05-12 SG SG10201402280QA patent/SG10201402280QA/en unknown
- 2010-05-12 RS RS20150758A patent/RS54386B8/sr unknown
- 2010-05-12 TW TW103134405A patent/TW201503888A/zh unknown
- 2010-05-12 CN CN201410226767.6A patent/CN104230900B/zh active Active
- 2010-05-12 CA CA2886322A patent/CA2886322A1/en not_active Abandoned
- 2010-05-12 DK DK15180635.3T patent/DK3002281T3/en active
- 2010-05-12 ES ES17190692T patent/ES2758726T3/es active Active
- 2010-05-12 SI SI201031290T patent/SI2873665T1/sl unknown
- 2010-05-12 EP EP15180635.3A patent/EP3002281B1/en active Active
- 2010-05-12 EP EP19193481.9A patent/EP3626716A1/en not_active Withdrawn
- 2010-05-12 CN CN201410226959.7A patent/CN104211689B/zh active Active
- 2010-05-12 MX MX2019003738A patent/MX376550B/es active IP Right Grant
- 2010-05-12 DK DK14175539.7T patent/DK2873665T3/en active
- 2010-05-12 JP JP2012510987A patent/JP5582662B2/ja active Active
- 2010-05-12 CN CN201080029503.1A patent/CN102596936B/zh active Active
- 2010-05-12 NZ NZ596444A patent/NZ596444A/en unknown
- 2010-05-12 KR KR1020207001908A patent/KR20200011049A/ko not_active Ceased
- 2010-05-12 ME MEP-2016-215A patent/ME02536B/me unknown
- 2010-05-12 SI SI201031950T patent/SI3309157T1/sl unknown
- 2010-05-12 LT LTEP14175539.7T patent/LT2873665T/lt unknown
- 2010-05-12 DK DK10720970.2T patent/DK2430014T3/en active
- 2010-05-12 RS RS20171281A patent/RS56654B8/sr unknown
- 2010-05-12 TW TW099115093A patent/TWI465444B/zh active
- 2010-05-12 PT PT171906928T patent/PT3309157T/pt unknown
- 2010-05-12 CN CN201410226164.6A patent/CN103977406B/zh active Active
- 2010-05-12 AP AP2016008993A patent/AP2016008993A0/xx unknown
- 2010-05-12 KR KR1020177009423A patent/KR20170041924A/ko not_active Ceased
- 2010-05-12 AU AU2010249043A patent/AU2010249043B2/en active Active
- 2010-05-12 KR KR1020147016504A patent/KR101503752B1/ko active Active
- 2010-05-12 PE PE2011001965A patent/PE20120509A1/es active IP Right Grant
- 2010-05-12 NZ NZ706236A patent/NZ706236A/en unknown
- 2010-05-12 EA EA201190259A patent/EA021974B1/ru active Protection Beyond IP Right Term
- 2010-05-12 PT PT107209702T patent/PT2430014E/pt unknown
- 2010-05-12 KR KR1020117029699A patent/KR101546119B1/ko active Active
- 2010-05-12 TW TW104133224A patent/TW201617073A/zh unknown
- 2010-05-12 EA EA201590073A patent/EA027493B1/ru unknown
- 2010-05-12 WO PCT/US2010/034600 patent/WO2010132601A1/en not_active Ceased
- 2010-05-12 PT PT151806353T patent/PT3002281T/pt unknown
- 2010-05-12 AP AP2011005987A patent/AP3622A/xx active
- 2010-05-12 TW TW103134406A patent/TWI547495B/zh active
- 2010-05-12 AR ARP100101639A patent/AR076765A1/es not_active Application Discontinuation
- 2010-05-12 EP EP10720970.2A patent/EP2430014B1/en active Active
- 2010-05-12 PL PL10720970T patent/PL2430014T3/pl unknown
- 2010-05-12 EA EA201490854A patent/EA026536B1/ru unknown
- 2010-05-12 HU HUE14175539A patent/HUE030465T2/hu unknown
- 2010-05-12 KR KR1020197007083A patent/KR20190029771A/ko not_active Ceased
- 2010-05-12 CN CN201410227599.2A patent/CN104016971B/zh active Active
- 2010-05-12 PT PT141755397T patent/PT2873665T/pt unknown
- 2010-05-12 NZ NZ61920510A patent/NZ619205A/en unknown
- 2010-05-12 UA UAA201413049A patent/UA121454C2/uk unknown
- 2010-05-12 ES ES10720970.2T patent/ES2548156T3/es active Active
- 2010-05-12 ME MEP-2015-196A patent/ME02321B/me unknown
- 2010-05-12 BR BR122014012810A patent/BR122014012810B1/pt active IP Right Grant
- 2010-05-12 PL PL15180635T patent/PL3002281T3/pl unknown
- 2010-05-12 SI SI201031024T patent/SI2430014T1/sl unknown
- 2010-05-12 TW TW105117036A patent/TWI629981B/zh active
- 2010-05-12 SG SG2011083151A patent/SG176015A1/en unknown
- 2010-05-12 TW TW107113373A patent/TWI689305B/zh active
- 2010-05-12 MX MX2014005805A patent/MX360803B/es unknown
- 2010-05-12 CN CN201611104976.9A patent/CN106588890B/zh active Active
- 2010-05-12 KR KR1020167017466A patent/KR101727876B1/ko active Active
- 2010-05-12 EP EP17190692.8A patent/EP3309157B1/en active Active
- 2010-05-12 EP EP14175539.7A patent/EP2873665B1/en active Active
- 2010-05-12 KR KR1020187006008A patent/KR20180028070A/ko not_active Ceased
- 2010-05-12 RS RS20160824A patent/RS55249B8/sr unknown
- 2010-05-12 BR BR122014013631A patent/BR122014013631B8/pt active IP Right Grant
- 2010-05-12 ME MEP-2017-262A patent/ME02916B/me unknown
- 2010-05-12 MX MX2011012058A patent/MX2011012058A/es active IP Right Grant
- 2010-05-12 ES ES14175539.7T patent/ES2596247T3/es active Active
- 2010-05-12 PL PL17190692T patent/PL3309157T3/pl unknown
- 2010-05-12 MX MX2014006862A patent/MX363732B/es unknown
- 2010-05-12 CN CN201811070551.XA patent/CN109020961A/zh active Pending
- 2010-05-12 US US12/779,023 patent/US8088368B2/en active Active
- 2010-05-12 UY UY0001032629A patent/UY32629A/es not_active Application Discontinuation
2011
- 2011-11-08 US US13/291,977 patent/US8273341B2/en active Active
- 2011-11-10 IL IL216254A patent/IL216254A/en active IP Right Grant
- 2011-11-11 MX MX2020011251A patent/MX2020011251A/es unknown
- 2011-11-11 CL CL2011002825A patent/CL2011002825A1/es unknown
- 2011-11-17 ZA ZA2011/08436A patent/ZA201108436B/en unknown
- 2011-11-30 CO CO11164618A patent/CO6470842A2/es active IP Right Grant
- 2011-12-12 EC EC2011011517A patent/ECSP11011517A/es unknown
2012
- 2012-06-07 US US13/491,446 patent/US8669234B2/en active Active
- 2012-07-19 US US13/553,517 patent/US8575118B2/en active Active
2013
- 2013-07-31 US US13/956,195 patent/US8822430B2/en active Active
- 2013-10-03 US US14/045,717 patent/US8841278B2/en active Active
2014
- 2014-05-16 US US14/280,478 patent/US9511056B2/en active Active
- 2014-05-23 JP JP2014107359A patent/JP5744283B2/ja active Active
- 2014-06-10 IL IL233044A patent/IL233044A/en active IP Right Grant
- 2014-06-10 IL IL233042A patent/IL233042A0/en unknown
- 2014-06-17 JP JP2014124325A patent/JP5745727B2/ja active Active
- 2014-07-17 IL IL233679A patent/IL233679B/en active IP Right Grant
- 2014-07-17 IL IL233678A patent/IL233678B/en active IP Right Grant
2015
- 2015-04-28 JP JP2015091474A patent/JP2015157842A/ja not_active Withdrawn
- 2015-11-17 CY CY20151101032T patent/CY1116942T1/el unknown
- 2015-11-19 SM SM201500284T patent/SMT201500284B/it unknown
2016
- 2016-01-07 HU HUS1600001C patent/HUS1600001I1/hu unknown
- 2016-01-11 LT LTPA2016002C patent/LTC2430014I2/lt unknown
- 2016-01-22 CY CY2016001C patent/CY2016001I1/el unknown
- 2016-02-05 FR FR16C0005C patent/FR16C0005I2/fr active Active
- 2016-02-17 NO NO2016004C patent/NO2016004I2/no not_active IP Right Cessation
- 2016-02-18 NL NL300796C patent/NL300796I2/nl unknown
- 2016-09-28 US US15/279,303 patent/US9981955B2/en active Active
- 2016-09-29 HR HRP20161242TT patent/HRP20161242T8/hr unknown
- 2016-10-04 CY CY20161100986T patent/CY1118048T1/el unknown
- 2016-10-05 SM SM201600351T patent/SMT201600351B/it unknown
2017
- 2017-05-12 JP JP2017095523A patent/JP2017145254A/ja not_active Withdrawn
- 2017-11-14 HR HRP20171759TT patent/HRP20171759T8/hr unknown
- 2017-12-06 CY CY20171101286T patent/CY1119684T1/el unknown
2018
- 2018-10-05 HK HK18112717.7A patent/HK1253517B/en unknown
- 2018-12-25 JP JP2018240826A patent/JP2019104732A/ja not_active Withdrawn
2020
- 2020-09-24 JP JP2020159623A patent/JP2021001214A/ja active Pending
- 2020-12-18 NO NO2020046C patent/NO2020046I1/no unknown

Also Published As

Publication number	Publication date
RS56654B8 (sr)	2021-06-30
JP2012526838A (ja)	2012-11-01
KR101503752B1 (ko)	2015-03-18
EP3309157B1 (en)	2019-09-04
KR20180028070A (ko)	2018-03-15
EA021974B1 (ru)	2015-10-30
HUE036906T2 (hu)	2018-08-28
KR101546119B1 (ko)	2015-08-20
MX2019003738A (es)	2019-07-01
CN102596936A (zh)	2012-07-18
RS54386B8 (sr)	2021-06-30
PL2873665T3 (pl)	2017-01-31
CN106588890A (zh)	2017-04-26
EP3309157A1 (en)	2018-04-18
BR122014013631B1 (pt)	2020-11-17
NL300796I2 (it)	2016-06-30
CN104211713A (zh)	2014-12-17
ZA201108436B (en)	2013-01-30
CN102596936B (zh)	2014-06-11
TWI629981B (zh)	2018-07-21
CN104230900A (zh)	2014-12-24
US9511056B2 (en)	2016-12-06
HK1162518A1 (en)	2012-08-31
SI2873665T1 (sl)	2017-02-28
EP2857394A1 (en)	2015-04-08
CN103977406A (zh)	2014-08-13
CO6470842A2 (es)	2012-06-29
IL233042A0 (en)	2014-07-31
IL233044A0 (en)	2014-07-31
CL2011002825A1 (es)	2012-10-12
IL233679A0 (en)	2014-09-30
HRP20161242T1 (hr)	2016-11-18
FR16C0005I1 (it)	2016-03-25
RS56654B1 (sr)	2018-03-30
BRPI1010795A2 (pt)	2016-12-20
ME02536B (me)	2017-02-20
CY2016001I2 (el)	2018-01-10
US8575118B2 (en)	2013-11-05
IL233679B (en)	2019-05-30
HUE030465T2 (hu)	2017-05-29
HUS1600001I1 (hu)	2016-02-29
KR20170041924A (ko)	2017-04-17
EA037281B1 (ru)	2021-03-04
HRP20171759T1 (hr)	2017-12-29
CY2016001I1 (el)	2018-01-10
CY1118048T1 (el)	2018-03-07
DK2873665T3 (en)	2016-11-07
MX376550B (es)	2025-03-07
NO3002281T3 (it)	2018-02-10
PT2430014E (pt)	2015-10-20
BR122014013631A2 (pt)	2017-06-27
SMT201700570T1 (it)	2018-01-11
JP2014148550A (ja)	2014-08-21
HRP20161242T8 (hr)	2021-05-14
CN104016971A (zh)	2014-09-03
KR20200011049A (ko)	2020-01-31
EP3002281B1 (en)	2017-09-13
AU2010249043A1 (en)	2011-12-01
AP3622A (en)	2016-03-02
BR122014012810A2 (pt)	2017-06-27
EP3002281A1 (en)	2016-04-06
HRP20171759T8 (hr)	2021-05-14
US8088368B2 (en)	2012-01-03
AR076765A1 (es)	2011-07-06
ES2646131T3 (es)	2017-12-12
JP5745727B2 (ja)	2015-07-08
AP2011005987A0 (en)	2011-12-31
PL3002281T3 (pl)	2018-02-28
TW201504244A (zh)	2015-02-01
IL233678B (en)	2019-05-30
ES2758726T3 (es)	2020-05-06
IL233044A (en)	2015-07-30
EA201590073A1 (ru)	2015-06-30
US9981955B2 (en)	2018-05-29
CY1119684T1 (el)	2018-04-04
IL216254A0 (en)	2012-01-31
TW201105656A (en)	2011-02-16
PE20150202A1 (es)	2015-02-13
NO2016004I2 (no)	2016-02-29
US20140249074A1 (en)	2014-09-04
US20120264711A1 (en)	2012-10-18
HK1223365A1 (en)	2017-07-28
EA201190259A1 (ru)	2013-01-30
MX2011012058A (es)	2012-04-02
CA2761258A1 (en)	2010-11-18
CN106588890B (zh)	2020-11-27
KR20190029771A (ko)	2019-03-20
JP2014169331A (ja)	2014-09-18
EA201490853A1 (ru)	2014-09-30
MX2020011251A (es)	2020-11-12
LT3002281T (lt)	2017-12-11
NZ619205A (en)	2015-04-24
ES2596247T3 (es)	2017-01-05
PL2430014T3 (pl)	2016-02-29
TWI547495B (zh)	2016-09-01
BRPI1010795B1 (pt)	2018-12-11
FR16C0005I2 (fr)	2016-09-30
BR122014013631B8 (pt)	2021-05-25
AU2010249043B2 (en)	2014-10-09
CN104016971B (zh)	2016-05-25
SI3002281T1 (sl)	2017-11-30
EP2430014A1 (en)	2012-03-21
PT3002281T (pt)	2017-11-14
TW201632183A (zh)	2016-09-16
NO2016004I1 (no)	2016-02-17
SG176015A1 (en)	2011-12-29
SI2430014T1 (sl)	2015-10-30
EA201490854A1 (ru)	2014-09-30
CY1116942T1 (el)	2017-04-05
JP2015157842A (ja)	2015-09-03
BR122014012810B1 (pt)	2020-04-14
EP2873665A1 (en)	2015-05-20
EP2873665B1 (en)	2016-07-06
DK3002281T3 (en)	2017-12-18
IL216254A (en)	2016-08-31
TWI465444B (zh)	2014-12-21
WO2010132601A1 (en)	2010-11-18
RS54386B1 (sr)	2016-04-28
JP2021001214A (ja)	2021-01-07
KR101727876B1 (ko)	2017-04-17
MX360803B (es)	2018-11-16
NO2020046I1 (no)	2020-12-18
NZ706236A (en)	2016-07-29
JP2017145254A (ja)	2017-08-24
EP3626716A1 (en)	2020-03-25
CN103977406B (zh)	2016-10-19
EP2430014B1 (en)	2015-08-19
CN104230900B (zh)	2018-10-19
ECSP11011517A (es)	2012-01-31
ES2548156T3 (es)	2015-10-14
US20140039021A1 (en)	2014-02-06
MX363732B (es)	2019-04-01
KR20160084478A (ko)	2016-07-13
TW202042807A (zh)	2020-12-01
KR20140122706A (ko)	2014-10-20
SI3309157T1 (sl)	2020-02-28
US20130137877A1 (en)	2013-05-30
US20120157404A1 (en)	2012-06-21
HK1253517B (en)	2020-04-24
TW201503888A (zh)	2015-02-01
PE20120509A1 (es)	2012-05-09
AP2016008993A0 (en)	2016-01-31
LTPA2016002I1 (lt)	2021-01-11
HK1253517A1 (en)	2019-06-21
EA026536B1 (ru)	2017-04-28
SG10201402280QA (en)	2014-08-28
JP5744283B2 (ja)	2015-07-08
CN104211689B (zh)	2017-01-18
DK2430014T3 (en)	2015-11-30
LT2873665T (lt)	2016-10-25
EA201790515A1 (ru)	2018-10-31
TW201902477A (zh)	2019-01-16
US20140051656A1 (en)	2014-02-20
US8822430B2 (en)	2014-09-02
ME02321B (me)	2016-06-20
SMT201500284B (it)	2016-01-08
US20100310512A1 (en)	2010-12-09
TW201617073A (zh)	2016-05-16
TWI689305B (zh)	2020-04-01
LTC2430014I2 (lt)	2021-02-25
JP5582662B2 (ja)	2014-09-03
PT3309157T (pt)	2019-12-02
EA027493B1 (ru)	2017-07-31
ME02916B (me)	2018-10-20
RS55249B8 (sr)	2021-06-30
PT2873665T (pt)	2016-10-13
CN104211689A (zh)	2014-12-17
IL233678A0 (en)	2014-09-30
HK1207638A1 (en)	2016-02-05
US8841278B2 (en)	2014-09-23
UA121454C2 (uk)	2020-06-10
CA2761258C (en)	2015-08-04
CN109020961A (zh)	2018-12-18
PL3309157T3 (pl)	2020-03-31
US20170029408A1 (en)	2017-02-02
HRP20151000T1 (hr)	2015-11-20
JP2019104732A (ja)	2019-06-27
CA2886322A1 (en)	2010-11-18
HUE025983T2 (en)	2016-05-30
RS55249B1 (sr)	2017-02-28
KR20140014393A (ko)	2014-02-06
UY32629A (es)	2010-12-31
US8273341B2 (en)	2012-09-25
US8669234B2 (en)	2014-03-11
NZ596444A (en)	2014-01-31
MX360800B (es)	2018-11-16
KR20140122705A (ko)	2014-10-20
HRP20151000T8 (hr)	2021-05-14
CN104211713B (zh)	2017-04-12

Publication	Publication Date	Title
SMT201600351B (it)	2016-11-10	Composti antivirali
CY2017026I2 (el)	2017-11-14	Τετρακυκλικη ενωση
SMT201600008B (it)	2016-02-25	Composti di piridazinone
DK2427449T3 (da)	2013-04-22	Vinylindazolylforbindelser
BR112012006859A2 (pt)	2019-09-24	compostos
BR112012005616A2 (pt)	2016-06-21	compostos antivirais heterocíclicos
BRPI1010852A2 (pt)	2019-09-24	compostos antivirais heterocíclicos
BRPI1008774A2 (pt)	2016-03-08	espiroamida substituída
BRPI1013614A2 (pt)	2019-09-24	compostos substituídos de espiro-amida
DE112010004215A5 (de)	2012-08-23	Hydrostataktor
DE112010002949A5 (de)	2012-09-06	Kupplungstastpunkte
BRPI1005525A2 (pt)	2016-02-23	compostos de azaazuleno
DK2511282T3 (da)	2014-07-07	Uracylspirooxetannukleosider
BRPI1013868A2 (pt)	2016-04-05	composto diaciletilenodiamina
BRPI1008827A2 (pt)	2016-02-23	deisobutenizador
BRPI1016266A2 (pt)	2019-09-24	compostos antivirais heterocíclicos
DE112010002728A5 (de)	2012-06-21	Turboinhalator
DE112010004249A5 (de)	2012-11-29	Spindelaktor
DE112009005323A5 (de)	2012-07-26	Hebelarmprüfmaschine
DE112009005462T8 (de)	2013-03-28	Lenkungsssteuervorrichtung
BR112012004964A2 (pt)	2016-04-05	girocóptero
BRPI1008070A2 (pt)	2016-03-15	tricianoboratos
EP2446176A4 (en)	2016-12-14	CYLINDER SEAL
DE112010003255A5 (de)	2013-05-02	Fördergutverteiler
BRPI1010159A2 (pt)	2016-03-29	bistuti